{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T23:07:56Z","timestamp":1720220876856},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.thromres.2016.02.021","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T04:15:21Z","timestamp":1456200921000},"page":"22-27","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Isotypic analysis of antibodies against activated Factor VII in patients with Factor VII deficiency using the x-MAP technology"],"prefix":"10.1016","volume":"141","author":[{"given":"Caroline","family":"Pfeiffer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve","family":"Mathieu-Dupas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Logghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9raldine","family":"Lissalde-Lavigne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Balicchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umran","family":"Caliskan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Laune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Fran\u00e7ois","family":"Schved","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel","family":"Giansily-Blaizot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2016.02.021_bb0005","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1538-7836.2004.00802.x","article-title":"Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX","volume":"2","author":"Lollar","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.02.021_bb0010","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1160\/TH10-10-0668","article-title":"Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors","volume":"105","author":"Lebreton","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.02.021_bb0015","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2141.2007.06657.x","article-title":"Inhibitor development in haemophilia B: an orphan disease in need of attention","volume":"138","author":"DiMichele","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2016.02.021_bb0020","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0029-1225762","article-title":"Factor VII deficiency","volume":"35","author":"Mariani","year":"2009","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2016.02.021_bb0025","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3324\/haematol.2012.074039","article-title":"Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER)","volume":"98","author":"Napolitano","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2016.02.021_bb0030","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1365-2141.2010.08287.x","article-title":"Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation \u2014 the surgical STER","volume":"152","author":"Mariani","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2016.02.021_bb0035","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood.V66.6.1284.1284","article-title":"Hereditary factor VII deficiency: heterogeneity defined by combined functional and immunochemical analysis","volume":"66","author":"Triplett","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2016.02.021_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/380041a0","article-title":"The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor","volume":"380","author":"Banner","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2016.02.021_bb0045","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1055\/s-0037-1613157","article-title":"Model of a ternary complex between activated factor VII, tissue factor and factor IX","volume":"88","author":"Chen","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.02.021_bb0050","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1021\/bi981951g","article-title":"Regulation of the catalytic function of coagulation factor VIIa by a conformational linkage of surface residue Glu 154 to the active site","volume":"38","author":"Shobe","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.thromres.2016.02.021_bb0055","doi-asserted-by":"crossref","first-page":"11631","DOI":"10.1021\/bi00204a026","article-title":"Factor VIIa residue Arg290 is required for efficient activation of the macromolecular substrate factor X","volume":"33","author":"Ruf","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.thromres.2016.02.021_bb0060","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nsb0695-504","article-title":"Structure of the Ca2+-free GLA domain sheds light on membrane binding of blood coagulation proteins","volume":"2","author":"Sunnerhagen","year":"1995","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.thromres.2016.02.021_bb0065","first-page":"119","article-title":"Antigenicity of activated recombinant factor VII followed through nine years of clinical experience","volume":"9","author":"Nicolaisen","year":"1998","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2016.02.021_bb0070","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0038-1650554","article-title":"Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use","volume":"76","author":"Nicolaisen","year":"1996","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.02.021_bb0075","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1600-0609.2007.00916.x","article-title":"Molecular analysis in a patient with severe factor VII deficiency and an inhibitor: report of a novel mutation (S103G)","volume":"79","author":"Pruthi","year":"2007","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.thromres.2016.02.021_bb0080","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1538-7836.2005.01225.x","article-title":"Inhibitor to factor VII in severe factor VII deficiency: detection and course of the inhibitor response","volume":"3","author":"Ingerslev","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.02.021_bb0085","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1111\/hae.12376","article-title":"Inhibitors to factor VII in congenital factor VII deficiency","volume":"20","author":"Batorova","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2016.02.021_bb0090","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1160\/TH14-03-0198","article-title":"Coagulation factor VII variants resistant to inhibitory antibodies","volume":"112","author":"Branchini","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.02.021_bb0095","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1160\/TH07-08-0497","article-title":"Simultaneous detection and epitope mapping of anti-factor VIII antibodies","volume":"99","author":"Lavigne-Lissalde","year":"2008","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.02.021_bb0100","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/jth.12846","article-title":"Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with haemophilia A","volume":"13","author":"Lapalud","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.02.021_bb0105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0038-1653759","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability","volume":"73","author":"Verbruggen","year":"1995","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.02.021_bb0110","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/j.1365-2516.2011.02666.x","article-title":"Successful prophylactic use of recombinant activated factor VII (rFVIIa) in a patient with congenital FVII deficiency and inhibitors to FVII","volume":"18","author":"Tokgoz","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2016.02.021_bb0115","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/blood-2008-08-174987","article-title":"Quantitation of anti-factor VIII antibodies in human plasma","volume":"113","author":"Krudysz-Amblo","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2016.02.021_bb0120","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-0037-1614229","article-title":"Characterization of monoclonal anti-human factor VII antibody (B101\/B1) that recognized three-dimensional structures near Arg at position 79 in the first EGF-like domain","volume":"79","author":"Takamiya","year":"1998","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.02.021_bb0125","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1055\/s-0037-1613257","article-title":"Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients","volume":"88","author":"Reding","year":"2002","journal-title":"Thromb. Haemost."},{"issue":"Suppl. 6","key":"10.1016\/j.thromres.2016.02.021_bb0130","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2516.2006.01363.x","article-title":"Immunological aspects of inhibitor development","volume":"12","author":"Reding","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2016.02.021_bb0135","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2141.2008.07232.x","article-title":"IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A","volume":"142","author":"Van Helden","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2016.02.021_bb0140","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0049-3848(96)00136-3","article-title":"Measurement of anti-factor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates","volume":"83","author":"Sawamoto","year":"1996","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2016.02.021_bb0145","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1182\/blood.V96.13.4370","article-title":"A new mutation in the HNF4 binding region of the factor VII promoter in a patient with severe factor VII deficiency","volume":"96","author":"Carew","year":"2000","journal-title":"Blood"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384816300494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384816300494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T19:53:06Z","timestamp":1600199586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384816300494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":29,"alternative-id":["S0049384816300494"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2016.02.021","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isotypic analysis of antibodies against activated Factor VII in patients with Factor VII deficiency using the x-MAP technology","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2016.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}